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Introduction
Patients presenting with psychiatric symptoms after focal brain 
damage challenge the boundaries between neurology and psy-
chiatry (1, 2). Such cases are of interest as they can provide causal 
links between brain regions or circuits and specific psychiatric 
symptoms, and lead to identification of therapeutic targets (3, 
4). However, judging whether new-onset psychiatric symptoms 
are attributable to a structural brain lesion can be complicated 
by incidental findings on neuroimaging (5), potential delays 
between the lesion and the resulting symptoms (6), and because 
the same symptoms can be caused by damage to multiple 
different brain regions (7).
Mania is a paradigmatic example. It is characteristic of 
bipolar I disorder, but has been reported following focal brain 
lesions for nearly a century (8). In seminal work by Starkstein 
and Robinson, lesions associated with mania were found to be 
more common in the right hemisphere, but occurred in numer-
ous different brain regions (9–19). These authors hypothesized 
that lesions causing mania may map to a limbic circuit involving 
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large database of healthy volunteers (n = 1000) (23, 24). By 
mapping symptoms to brain networks, rather than single 
brain regions, this technique has lent insight into mechanisms 
underlying a variety of neuropsychiatric symptoms (4, 20, 25, 
26). Here, it was applied to 2 independent cohorts of lesions 
associated with mania.
the orbitofrontal cortex, basotemporal cortex, and basal ganglia 
(9–19). A recently developed technique, termed lesion network 
mapping, is well suited to test this hypothesis (3, 20). Rather 
than focus on lesion locations alone, this approach examines 
the network of regions functionally connected to each lesion, 
using resting-state functional connectivity (21, 22) from a 
Figure 1. Lesional mania 
cohorts CONSORT diagrams. 
Forty-one and 15 lesional mania 
cases were included in our liter-
ature (A) and clinical (B) lesional 
mania cohorts, respectively.
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3). Similar to prior work (3, 20), we computed functional connec-
tivity between each lesion location and the rest of the brain using 
resting-state functional MRI (rs-fMRI) data from a large norma-
tive cohort (n = 1000) (23, 24). The connectivity pattern of mania 
lesions was then compared with that of control lesions also derived 
from the literature, but not associated with mania symptoms (n = 
79) (20, 27, 28). We found significant differences in lesional con-
nectivity between the 2 groups, with peaks in the right orbitofron-
tal cortex and right temporal cortex (Figure 3 and Supplemental 
Figure 2). We refer to this map as a “mania lesion network,” with 
lesion locations associated with mania intersecting positive nodes 
in this network map (Figure 3F), and control lesions not associated 
with mania intersecting neutral or negative nodes (not shown).
Reliability, validation, reproducibility, and robustness. To asses 
reliability of tracing methods, all 41 literature-based lesions were 
retraced by a different researcher, who was blind to the original 
lesion tracings. Lesion masks produced by the 2 tracers were very 
similar. The median distance between the center of gravity of trac-
ings for the same lesion (8 mm, 3 voxels) was significantly smaller 
Results
Deriving a mania network from brain lesions in the literature. Our 
systematic literature search identified 41 brain lesions associ-
ated with mania and fulfilling inclusion and exclusion criteria 
(Figure 1A, literature cohort. See supplemental material for 
details, available online with this article; https://doi.org/10.1172/
JCI136096DS1). The mean age of patients was 54.9 ± 17.7 years 
and the most common symptoms were mood elation/irritability, 
increased energy, increase in goal-directed activity, and psycho-
motor agitation. Pressured speech and decreased need for sleep 
were also very common. The time between lesion and symptom 
onset ranged from hours to years, with a median time of 3 years 
(Supplemental Table 1). When these lesion locations were mapped 
to a common brain atlas, they were found to be neuroanatomically 
diverse, involving a wide range of cortical and subcortical areas 
(Figure 2 and Supplemental Figure 1). No single brain region was 
lesioned in all or even most cases.
Given this heterogeneity, we next tested whether these lesion 
locations shared a specific pattern of brain connectivity (Figure 
Figure 2. Lesions associated with mania occur in multiple different brain locations. Six representative lesions (green) selected from 41 literature cases 
demonstrate heterogeneity in lesion location.
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than that between different lesions (51 mm, 26 
voxels, P < 0.0001). When our mania lesion net-
work was recomputed using lesion masks from 
the independent tracer, results were nearly 
identical to the original network (spatial cor-
relation of 0.96). For additional details see Sup-
plemental Figure 3.
To validate the mania network derived 
from literature-based lesions, we identified a 
second cohort of lesion-induced mania cases 
based on clinical chart review (Figure 1B). 
These 15 cases were of similar age (54.9 ± 17.0 
years) and had similar mania symptoms com-
pared with our original literature cohort (Sup-
plemental Table 2). However, the lesions were 
located in different brain areas (Supplemental 
Figure 1). For example, the region of maximum 
lesion overlap in our literature cohort only 
intersected 1 lesion in our clinical cohort, while 
the region of maximum overlap in our clinical 
cohort did not intersect any lesion in our litera-
ture cohort (Supplemental Figure 1). However, 
lesion locations from the clinical cohort did 
intersect the mania lesion network map derived 
from the literature cohort (Figure 4, A and B). 
Lesion locations from the clinical mania cohort 
demonstrated significantly more overlap with 
positive nodes of the literature-based mania 
lesion network map when compared with more 
than 490 clinical control lesions not associated 
with mania (P < 0.05).
To assess reproducibility, we computed a 
new mania lesion network map by comparing 
the connectivity of clinical mania lesions to 
that of clinical control lesions (Figure 4C). This 
clinical mania lesion network map aligned well 
with the mania lesion network derived from the 
literature cohorts (Figure 4B). A conjunction 
analysis identified connections significantly 
associated with mania across both independent 
cohorts (Figure 4D), while a combined analysis 
across both data sets identified connections 
most strongly associated with mania, even 
at a rigorous statistical threshold of α less than 
1.0 × 10–4 (Figure 4E; see Supplemental Figures 
2 and 4 for additional detail). The most signifi-
cant connections in this combined map were the 
right orbitofrontal cortex (Montreal Neurologic 
Institute [MNI] 42, 42, –20), right lateral tempo-
ral cortex (MNI 50, –26, –16), and right frontal 
polar cortex (MNI 12, 54, –14) (Figure 4E and 
Supplemental Table 3).
Our combined mania lesion network was 
robust in controlling for various confounds. Spe-
cifically, it remained similar when controlling for 
lesion size (Figure 5A) when using different sets 
of control lesions, including lesions associated 
Figure 3. Deriving a mania network from brain lesions in the literature. The location of brain 
damage associated with mania (A) or with other unrelated symptoms (B) was identified based 
on published images and mapped to the MNI standard brain atlas. (C and D) Brain regions 
functionally connected to each lesion location were identified based on a large normative 
resting-state functional connectivity database connectivity database (N = 1000). Results were 
combined across the 1000 subjects to generate a statistical T map for each lesion. Statistically 
significant differences in functional connectivity between mania lesions (n = 41) and control 
lesions (n = 79) define a “mania lesion network map.” In this map (E), regions more connected 
to mania lesions are shown in warm colors, while regions more connected to control regions are 
shown in cool colors. (F) Lesion locations from literature mania cases (green) overlap positive 
nodes in the network. Maps in E and F were obtained using a voxel-wise permutation-based 
2-sample t test performed within FSL PALM (2000 permutations) and are displayed at an 
FWE-corrected level of P < 0.05.
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sected the combined mania lesion network (20, 25, 26, 29–31). 
We found that lesion locations associated with criminality and 
delusions intersected the mania network more than lesion loca-
tions associated with movement disorders or hallucinations (P < 
0.0001; Figure 6, C and D).
Therapeutic relevance of the mania lesion network. Finally, we 
explored whether the combined mania lesion network aligns with 
previously reported effects of brain stimulation on mania symp-
toms (Figure 7, A–F). Specifically, high-frequency repetitive tran-
scranial magnetic stimulation (rTMS) of the right dorsolateral 
prefrontal cortex (DLPFC) appears to be beneficial for mania 
(32–35), but high-frequency stimulation of the left DLPFC, used 
as treatment for depression, may induce manic symptoms (36, 37). 
Consistent with these reports, we found that left and right DLPFC 
regions of interest (ROIs) encompassing these rTMS targets have 
opposite connectivity to the mania network map (P < 0.0001; 
Figure 7, A and B). Moreover, rTMS treatment protocols targeting 
the right DLPFC using the 5-cm rule (34, 35, 38) reported greater 
improvement in mania symptoms than a treatment protocol tar-
geting a more anterolateral location (39). Consistent with these 
reports, the 5-cm target is more connected to our mania network 
map than the less effective anterolateral target (P < 0.0001; Fig-
ure 7, C and D). Given this preliminary evidence, we identified 
the peak positive connectivity site of the mania network map in 
the right DLPFC (MNI 20, 36, 52), and peak negative connectiv-
ity sites in the left DLPFC (MNI –20, 2, 64 and –36, 44, 38), for 
with other psychiatric symptoms (Figure 5B), or when considering 
time between lesion and symptom onset in the analyses (Figure 5, 
C and D). The network also remained similar when analyses were 
restricted to the subset of patients with all core mania symptoms 
(Figure 5E), patients with absent personal or family history of neu-
ropsychiatric syndromes (Figure 5F), those with acute ischemic 
stroke as the etiology for brain lesions (Figure 5G), or those with 
all these restrictions combined (Figure 5H).
Diagnostic relevance of the mania lesion network. To explore 
potential clinical applications of such a mania lesion network, 
it was used to analyze a diagnostically challenging case, pub-
lished after our original literature search (2). In this case, 
new-onset mania symptoms were attributed to an acute 
stroke-induced lesion, in the presence of chronic brain lesions 
and prior mania-like symptoms. Based on intersection of the 
lesion locations from this case with our combined mania lesion 
network (Figure 6, A and B), we found that the acute brain lesion 
was unlikely to contribute to mania symptoms (1.3% probability 
of falling within the mania lesion distribution, 67% probability 
of falling within the control lesion distribution). In contrast, 1 of 
the older lesions was a more likely contributor (46% probability 
of falling within the mania distribution, <1% probability of fall-
ing within the control distribution).
Relationship of the mania lesion network to lesion locations caus-
ing other symptoms. In an exploratory analysis, we tested whether 
lesion locations causing other neuropsychiatric symptoms inter-
Figure 4. Validation and replication of lesion mania network with an independent data set. (A) Lesion locations from a clinical mania lesion cohort 
(green, 6 of 15 lesions shown) intersect positive nodes in the mania lesion network map derived from literature cohorts. The mania lesion network map 
derived from literature cohorts (n = 41 vs. 79 mania vs. control lesions) (B) was reproducible when using data from clinical cohorts (n = 15 vs. n = 490 mania 
vs. control lesions) (C). A conjunction analysis shows significant regions identified across both mania lesion network maps (overlap of B and C) (D) and a 
single mania lesion network map combining both literature and clinical cohorts shows regions that are strongly associated with mania when using a high 
statistical threshold (n = 56 vs. n = 569 mania vs. control lesions) (E). Connectivity maps were obtained using a voxel-wise permutation-based 2-sample 
t test performed within FSL PALM (2000 permutations). Connectivity maps in A and C are displayed at an FWE-corrected level of P < 0.05. Connectivity 
maps in B and E are displayed at more stringent FWE-corrected levels (P < 3.0 × 10–4 and P < 1.0 × 10–4, respectively), in order to best show the peak regions 
of each map. For additional details on peak locations see Supplemental Table 3 and Supplemental Figure 5. The map in D was obtained by binarizing B and 
C and computing the sum of their overlap. The maps in B–E are at MNI space z = –18. Regions more connected to mania lesions are shown in warm colors, 
while regions more connected to control regions are shown in cool colors.
The Journal of Clinical Investigation C L I N I C A L  M E D I C I N E
5 2 1 4 jci.org   Volume 130   Number 10   October 2020
potential future use in rTMS trials (for additional details on peak 
locations see Supplemental Figure 5).
In similar analyses, we explored whether the mania lesion net-
work map aligns with reports of mania symptoms following deep 
brain stimulation (DBS). Specifically, mania has been reported 
following DBS of the ventral capsule/ventral striatum (VC/VS) 
for obsessive-compulsive disorder, but it does not occur in most 
patients (40). Consistent with our findings, the location of stim-
ulation associated with the occurrence of mania (41–44) is more 
connected to the mania lesion network than the standard location 
of stimulation (P < 0.0001; Figure 7, E and F, and ref. 45). Similarly, 
mania is considered a rare complication of subthalamic nucleus 
(STN) DBS for Parkinson’s disease (46), and stimulation sites that 
have been associated with mania (47–49) are more connected to 
our identified mania lesion network than the standard location of 
stimulation (P < 0.0001; Supplemental Figure 6 and ref. 50).
Discussion
Why some lesions, but not others, are associated with mania has 
remained unclear since the association was first noted nearly a cen-
tury ago (8). Despite heterogeneity in lesion location, we found that 
lesion locations associated with new-onset mania are characterized 
by connectivity to the right orbitofrontal cortex, right lateral tem-
poral cortex, and right frontal polar cortex. This result was repro-
ducible across independent lesion cohorts and aligns with reported 
effects of therapeutic brain stimulation on mania symptoms.
Our findings are based on lesion network mapping, a tech-
nique that has been successfully applied to hallucinations (20, 
51), delusions (25), criminality (26), depression (4), and many 
other neuropsychiatric symptoms (3). In fact, our study is not 
the first to apply lesion network mapping to mania, with a prior 
study also concluding that mania lesions show a distinct pat-
tern of brain connectivity (52). However, which connections 
are most important differ between the 2 studies, including the 
description of right-sided lateralization here. These differences 
are likely due to several methodological improvements in our 
study, including a larger mania cohort (n = 56 vs. 23) (53), a 
larger connectome data set (n = 1000 vs. 40) (26, 54), and a 
larger number of control lesions (n = 569 vs. 23). Our 41 liter-
ature lesions include 21 of the 23 lesions from this prior study 
(1 case was excluded due to being on antidepressants [ref. 55] 
and another case was published after our literature search [ref. 
56]). Our study also extends beyond prior work by investigating 
reproducibility in an independent mania lesion cohort (N = 15), 
Figure 5. Stability of mania lesion network when controlling for various confounds. The combined mania lesion network, using data from literature and 
clinical cohorts, remained similar when it was recomputed controlling for lesion size (n = 56 vs. n = 569 mania vs. control lesions) (A), when using a different 
set of control lesions (n = 56 vs. n = 409 mania vs. control lesions; see Methods for details) (B), and when using a subset of mania cases with shorter tempo-
ral association between lesion and symptom onset (n = 28 vs. n = 569 mania vs. control lesions) (C) or the remaining mania cases (n = 28 vs. n = 569 mania 
vs. control lesions; see Methods for details) (D). The lesion network was also similar when restricting analyses to subsets of lesional mania cases presenting 
with all core mania symptoms as listed in DSM 5 (n = 46 vs. n = 569 mania vs. control lesions) (E), with no personal or family history of relevant neuropsychi-
atric syndromes (n = 39 vs. n = 569 mania vs. control lesions) (F), caused by ischemic stroke (n = 23 vs. n = 569 mania vs. control lesions) (G), or accumulating 
all of the restrictions mentioned in E–G (n = 19 vs. n = 569 mania vs. control lesions) (H). Connectivity maps were obtained using a voxel-wise permutation- 
based 2-sample t test performed within FSL PALM (2000 permutations) and are displayed at an FWE-corrected level of P < 0.05, at MNI space z = –18. 
Regions more connected to mania lesions are shown in warm colors, while regions more connected to control lesions are shown in cool colors.
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and exploring diagnostic potential, relationship with lesion 
locations causing other neuropsychiatric symptoms, and 
therapeutic and iatrogenic relevance in TMS and DBS.
Our study found a clear right-sided lateralization of con-
nections specific to mania lesions. This lateralization was 
present both in the literature and clinical cohorts when ana-
lyzed independently, but it was most obvious when combining 
the data sets and focusing on only the most significant find-
ings (see Figure 4). This right lateralization is consistent with 
the valence hypothesis of mood laterality (10, 57) and prior 
right-lateralized findings in mania, including studies of lesion 
location (58, 59), lesion-induced hypoperfusion (16, 26, 60), 
brain stimulation (32–37), and neuroimaging findings in pri-
mary bipolar disorder (60–72). More specifically, our results 
show that lesion locations associated with mania are connected 
to the right orbitofrontal cortex and right lateral temporal cor-
tex, consistent with the longstanding hypothesis of Starkstein 
and Robinson (9–19).
Mania lesion network maps may be useful for determin-
ing whether a given lesion is related to mania symptoms, 
similar to prior work in delusions (73). Structural neuro-
imaging is increasingly acquired for workup of psychiatric 
symptoms, but incidental abnormalities are common (74). 
A recently published case report illustrates this diagnostic 
challenge for mania (2). In this case, a 61-year-old man pre-
sented to the emergency department with increased energy, 
irritability, euphoria, grandiosity, impulsive behavior, and 
decreased need for sleep. These manic symptoms had been 
present for over a month, but the lesion considered to be 
responsible for these symptoms was likely less than 5 days 
old based on brain imaging of the lesion (hyperintense in 
diffusion-weighted MRI and hypointense on apparent diffu-
sion coefficient MRI) (75, 76). Exploratory use of our mania 
lesion network map suggested that an older lesion was a 
more likely contributor to the patient’s mania symptoms 
than the acute lesion, which is consistent with the patient’s 
history of psychiatric symptoms, predating the acute lesion 
Figure 6. Intersection of our mania lesion network with other lesion 
locations. (A) We explored a diagnostically challenging case of lesional 
mania (2), where mania symptoms were attributed to an acute infarct. 
This acute infarct intersected a negative node of our mania lesion 
network, making it an unlikely contributor to mania symptoms. (B) In 
contrast, a previous lesion intersected a positive node of our network, 
consistent with a history of mania-like symptoms predating the 
acute infarct. (C) In a separate analysis, lesion locations associated 
with other neuropsychiatric symptoms, such as criminality (purple) 
and delusions (pink), intersected our mania lesion network map. (D) 
This intersection differed significantly across different neuropsy-
chiatric symptoms. The y axis in D represents the sum of the voxel 
intensities in the mania lesion network map at the location of each 
lesion. Connectivity maps in A–C were obtained using a voxel-wise 
permutation-based 2-sample t test performed within FSL PALM (2000 
permutations) and were corrected for multiple comparisons using 
threshold-free cluster enhancement and displayed at an FWE- 
corrected level of P < 0.05. Regions more connected to mania lesions 
are shown in warm colors, while regions more connected to control 
regions are shown in cool colors. ****P < 0.0001 in a general linear 
model controlling for lesion size.
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While the mania lesion map developed here may be relevant 
to address diagnostic questions, it is worth noting that there is 
overlap with lesional neuropsychiatric syndromes with overlap-
ping symptoms. In fact, an important and potentially novel aspect 
of the current study is the use of lesion network mapping to relate 
different lesion-induced symptoms to one another. We found that 
lesion locations associated with criminality (26) and delusions 
(25) showed strong intersection with the mania lesion network 
map, to a larger degree than lesion locations associated with other 
symptoms such as hallucinations. This is consistent with increased 
risk of criminal problems (90) and presence of delusions (91) in 
patients suffering from mania, as well as with a higher incidence 
of delusions compared with hallucinations in these patients (91). 
Lesion network mapping may thus prove useful for understand-
ing the neuroanatomical relationship between different comorbid 
neuropsychiatric symptoms, extending well beyond mania.
Similar to lesional syndromes, mania is considered a rare 
complication of DBS (40, 46). Our mania lesion network results 
are consistent with observed differences in mania resulting from 
different DBS electrode locations, for both the VC/VS and STN 
(2). However, it is important to emphasize that the mania lesion 
network maps developed here are maps of probability, rather 
than maps of regions where lesions will always cause mania. 
Many patients with lesions in the red-yellow area of our map will 
not present with clinically apparent mania. Mania is relatively 
rare following focal brain damage (<10%), compared with other 
symptoms such as depression (21%–33%) (77–80), which is con-
sistent with observed differences in global prevalence between 
primary bipolar disorder and major depressive disorder (81, 82), 
and the fact that depression is a more common reaction to any 
new medical condition (83). It is also possible that patients with 
lesions falling within our mania network will experience mild 
or subclinical symptoms, as recently shown for lesion network 
maps of depression (4), memory (84), and facial recognition 
(85). Finally, there are likely other factors that play a role in 
lesion-induced mania besides lesion location, including genetic 
(16, 86) and environmental (87–89) factors. Additional work, 
using larger cohorts, will be needed to determine the diagnostic 
utility of mania lesion networks, including for prediction of sub-
clinical mania symptoms.
Figure 7. Potential therapeutic relevance of the mania lesion network. (A) High-frequency repetitive transcranial magnetic stimulation (rTMS) of the right 
dorsolateral prefrontal cortex (red region) has been reported to improve mania symptoms (32–35, 92), while high-frequency rTMS and anodal transcranial 
direct current stimulation of the left dorsolateral prefrontal cortex (blue region) can induce mania (36, 37, 93–97). (B) These stimulation sites overlay areas 
of mostly positive connectivity in the mania lesion network map (red outline), and mostly negative connectivity (blue outline). (C) rTMS trials targeting a 
brain region identified with the 5-cm rule (red region) reported increased therapeutic efficacy for mania compared with trials targeting a region identified 
using the EEG F4 coordinate (blue region). (D) The more effective target intersects our mania lesion network (red outline), while the less effective target 
does not (blue outline). (E) Deep brain stimulation (DBS) sites reported to induce mania (red region) are slightly offset compared with the standard deep 
brain stimulation site in the ventral capsule/ventral striatum (VC/VS) (blue region). (F) The site reported to induce mania intersects our mania lesion 
network (red outline), while the standard site does not (blue outline). DBS sites in panels E and F are shown on a coronal brain slice (MNI space y = 7). 
Connectivity maps in B, D, and F were obtained using a voxel-wise permutation-based 2-sample t test performed within FSL PALM (2000 permutations). 
B and D are displayed at an FWE-corrected level of P < 0.05. In these panels, regions more connected to mania lesions are shown in warm colors, while 
regions more connected to control regions are shown in cool colors.
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tomic and functional substrates underlying mania and may help 
define future potential therapeutic targets for this complex neuro-
psychiatric syndrome.
Methods
Mania lesion cohort 1: 2D lesions from literature search. Cases of sec-
ondary lesional mania with available lesion images published until 
February 2017 were identified from a literature search according to a 
predefined protocol (107) following PRISMA guidelines (53). A full list 
of search terms and of the inclusion and exclusion criteria applied to 
this study is available in the supplemental material. Cases with trau-
matic or infectious etiology were excluded because brain damage may 
extend beyond what is apparent on structural imaging. Two investiga-
tors with expertise in psychiatry independently assessed eligibility and 
extracted clinical and demographic data, with consensus obtained, if 
necessary, with input from a senior psychiatrist. Two other investiga-
tors manually traced lesions onto a standardized brain atlas (MNI) 
using Medical Imaging Interaction Toolkit (MITK) software (http://
www.mitk.org), with a third investigator independently reviewing 
each lesion tracing. Because these lesion locations were traced from 
published images, they are 2D.
Mania lesion cohort 2: 3D lesions from clinical chart review. Clinical 
cases of secondary lesional mania were identified consecutively by 2 
psychiatrists from patients at the Neuropsychiatry Unit of the Psychi-
atry Department at Centro Hospitalar de Lisboa Ocidental (CHLO), 
according to protocol approved by the Ethics Committee of CHLO. 
Eligibility assessment and extraction of clinical and demographic 
data were performed as described for literature cases. From an ini-
tial cohort of 21 patients identified by chart review, 15 were eligible 
according to the inclusion and exclusion criteria described in the sup-
plemental material, with the remaining excluded due to treatment 
with corticosteroids and/or antidepressants (n = 3) or due to traumatic/ 
infectious etiology (n = 3). One investigator manually traced brain 
lesions on each MRI using MITK software, with independent review 
and corrections by another investigator. A third investigator coreg-
istered each traced lesion into MNI space using a composition of 3D 
rigid and affine transformations, and 3D cubic B-spline transforma-
tion, in 3D Slicer software (https://www.slicer.org/). The transformed 
lesion in atlas space was compared with the original radiologic lesion 
for verification of accuracy by 3 authors. Because these lesions were 
traced from the original MRI scans, they are 3D.
Deriving a mania network from brain lesions in the literature.  
rs-fMRI data from 1000 healthy subjects (23, 24) were used to gen-
erate a connectivity map for each lesion location, as described pre-
viously (20, 73, 108). Briefly, we computed the correlation between 
the average time-course of rs-fMRI activity from each lesion location 
with activity in every other brain voxel, using data from each of the 
healthy subjects (73, 109). Results were combined across the 1000 
subjects using a random-effects analysis to generate a lesion network 
map for each lesion location. To identify connections differing signifi-
cantly between mania and control lesions, these network maps were 
statistically compared with lesion network maps derived from control 
lesion locations, not associated with mania. Literature-derived con-
trol lesions associated with nonpsychiatric symptoms, such as apha-
sia, asterixis, freezing of gait, and poststroke pain (20, 110, 111), were 
used according to traces performed previously for the respective pub-
lications (n = 79). Statistical comparison between the mania-derived 
targets. Although speculative, our results may have implications 
for focal brain stimulation treatment of mania. High-frequency 
rTMS to the right DLPFC may be beneficial in mania (32–35, 92), 
with some right prefrontal rTMS sites appearing to be more effec-
tive than others (34, 35, 38, 39). On the other hand, high-frequency 
rTMS and anodal transcranial direct current stimulation (tDCS) of 
the left prefrontal cortex, used as treatment for depression, may 
induce manic symptoms (36, 37, 93–97). Although conclusions 
about these brain stimulation effects are based on limited data, 
our lesion network mapping results are consistent with the existing 
literature. Combined with prior work showing that lesion network 
mapping can identify effective brain stimulation targets in other 
disorders (3, 54, 98, 99) our results might be used to guide future 
brain stimulation trials for mania (32–35). For example, our results 
suggest an optimal rTMS target in the right prefrontal cortex (MNI 
20, 36, 52), with alternative targets in the right orbitofrontal cortex 
(MNI 42, 42, –20) and right inferior temporal gyrus (MNI 50, –26, 
–16), which will require prospective clinical validation.
Our study has several potential limitations. First, our litera-
ture cohort is susceptible to selection bias, error in lesion tracing, 
heterogeneity in imaging modality (CT vs. MRI), and inaccuracies 
that may result from using a 2-dimensional (2D) lesion to approx-
imate a 3D lesion volume. Similarly, our clinical cohort is limited 
by small sample size. However, all of these limitations would bias 
us away from finding a consistent localization and are unlikely 
to explain the significant results demonstrated here. Moreover, 
the fact that our results replicate across both cohorts suggest that 
limitations specific to 1 cohort are unlikely to explain our results. 
Consistency across our 2 cohorts is also consistent with prior work 
showing that lesion networks derived from 2D slices are very sim-
ilar to networks derived from 3D lesions (20, 100). Importantly, 
literature results were replicated in a smaller clinical cohort of 
MRI-defined 3D lesions, which are not subject to the same lim-
itations as our literature cohort. A second limitation of our study 
is that lesion network mapping focuses on the spatial component 
of lesion-induced symptoms, neglecting the temporal evolution of 
symptoms, brain remodeling in response to injury, and the dynamic 
process of compensation and/or recovery that could involve brain 
regions other than those connected to the lesion location. Further 
work using functional and structural neuroimaging at multiple 
time points in patients with lesion-induced mania is needed to 
chart this temporal evolution and assess the role of the regions 
implicated here in this process. Finally, any implications of these 
results for primary bipolar disorder must take into consideration 
that lesion-induced mania could have a different neuroanatom-
ical substrate than primary mania (74, 101, 102). The alignment 
of our lesion results with therapeutic effects of brain stimulation 
in primary mania suggests some overlap, but further work com-
paring the 2 is needed (for an example see ref. 52). Furthermore, 
this study focuses only on lesion location, while ignoring poten-
tial contributions from genetic loading (16, 86), environmental or 
treatment exposures (87–89), and the use of pharmacologic agents 
(103–106), with known impact in primary bipolar disorder.
In conclusion, we found that brain lesions associated with 
mania occur in a variety of different brain locations but share a 
specific connectivity profile, when compared with lesions not 
associated with mania. These results lend insight into neuroana-
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The combined (literature + clinical) mania lesion network map 
was then recomputed multiple times to assess robustness to a variety 
of different confounds. Importantly, we recomputed the map con-
trolling for lesion size, to ensure that differences in lesion size were 
not driving the observed connectivity differences between mania 
and control lesions. We tested whether our results were dependent 
on the temporal association between lesion onset and emergence of 
manic symptoms by repeating our analysis using 2 mania subgroups 
split according to the median time between lesion occurrence and the 
onset of mania symptoms: either lesions with documented temporal 
association of 3 years or less (n = 28) or lesions with a documented 
temporal association of more than 3 years, or unknown temporal asso-
ciation (n = 28). Analyses to test whether our results were being driven 
by choice of control lesions were performed in analyses maintaining 
the same mania lesions but changing control lesions. We replaced the 
original literature control cohort (n = 79) with an alternative literature 
control cohort consisting of different literature lesions included in 
previous publications by our group (n = 274), independent of whether 
the symptom profiles might overlap with those of mania and including 
numerous psychiatric symptoms (20, 25, 26, 29, 54). We also replaced 
our original clinical control cohort (n = 490) with an alternate clinical 
cohort of nonspecific lesions from a different source (n = 135) (116). 
Finally, to ensure results were independent of our inclusion criteria, 
we recomputed the combined (literature + clinical) mania lesion net-
work map for 4 different mania lesion subgroups: (a) patients with all 
core mania symptoms listed in DSM 5 (n = 46); (b) patients without a 
personal or family history of depression, mania, or psychotic disorders 
(n = 39); (c) patients in whom lesion etiology was exclusively ischemic 
stroke (n = 23); and (d) patients satisfying criteria a, b, and c (n = 19).
Diagnostic relevance of the mania lesion network. We assessed how a 
diagnostically challenging case, published after our original literature 
search (2), could be assessed using the combined mania connectivity 
network map. Specifically, we intersected all the 6 traceable lesions 
reported in that case with the combined mania connectivity network 
map, to obtain the sum of voxel intensities for each separate lesion, 
as described above for the intersection between clinical cohorts 
lesions and the literature connectivity network map. We then tested 
if the sum of voxel intensities of each individual lesion from this case 
report differed significantly from the distributions of the sums of voxel 
intensities for the literature mania lesions (n = 41) and for the litera-
ture control lesions (n = 79). Because these data did not fit a normal 
distribution, these comparisons were performed using a 1-sample Wil-
coxon’s signed-rank test, with the sum of voxel intensities for the case 
report lesions as the hypothesized values (Stata Statistical Software, 
release 15). This analysis returns the probability, i.e., P value, that the 
sum of voxel intensities for a given lesion is within the distribution of 
sums of voxel intensities in the comparison cohort (i.e., the mania or 
control literature cohort) (114). Probabilities for these analyses were 
reported as percentages instead of decimals (i.e., P = 0.05 is 5%), to 
facilitate interpretation (114).
Relationship of the mania lesion network to lesion locations causing 
other symptoms. We explored whether lesion locations associated with 
other neuropsychiatric symptoms intersected our combined mania 
lesion network map. Specifically, we examined lesion locations associ-
ated with criminality (n = 40) (26), delusions (n = 32) (25), hemichorea 
(n = 29) (29), alien limb (n = 53) (30), akinetic mutism (n = 28) (30), 
auditory hallucinations (n = 28) (20), parkinsonism (n = 29) (31) and 
and control-derived network maps was performed using a voxel-wise 
permutation-based 2-sample t test implemented within FSL PALM 
(https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/Randomise/UserGuide), with 
threshold-free cluster enhancement (TFCE), 2-tailed testing, and 
family-wise error (FWE) correction options. Two thousand permuta-
tions per test and α less than 0.05 were selected. Permutation-based 
statistics followed by FWE correction was used to reduce the risk of 
false positives (112), according to best practice guidelines for neuro-
imaging (113). The resulting voxel statistical map was defined as a 
“mania lesion network map.”
Reliability, validation, reproducibility, and robustness. In order to 
assess reliability of our tracing methodology, we tested if lesion loca-
tions and the resulting mania network map remained stable when 
literature lesions were traced by a different researcher, independent 
from the team performing tracing originally. To test lesion location 
reliability, we compared center of gravity distances obtained from 
tracing pairs from the same lesion (N = 41 pairs), to those obtained 
from tracing of pairs of distinct lesions (N = 820 pairs). Because these 
data did not fit a normal distribution, we performed Wilcoxon’s rank-
sum test (114) (Stata Statistical Software, release 15; StataCorp LLC). 
To test lesion network mapping reliability, we recomputed the mania 
lesion network map using the second set of literature tracings. The 
degree of similarity between mania lesion network maps was comput-
ed using Pearson’s spatial correlation.
Validation of the literature-based mania lesion network map 
was tested with data from an independent cohort of lesional mania. 
Specifically, we tested if the literature-based mania lesion network 
map could serve as a spatial template to anticipate the probability 
that a lesion location will result in mania symptoms. We thus test-
ed whether our independent data set of clinical mania lesions (n = 
15) intersected the literature-based mania lesion network map more 
than clinical control lesions. These 3D control lesions were obtained 
from a cohort of patients with stroke (n = 490), that were not selected 
for any particular symptom (115). For each mania or control lesion, 
we summed the intensities of voxels in the network map that 
intersected the lesion location, and then compared sums of voxel 
intensities between mania and control lesions. Comparisons were 
performed in a general linear model, controlling for lesion size, 
bootstrapping the standard error estimates (2000 permutations) 
(Stata Statistical Software, release 15).
Reproducibility across different cohorts was also tested using 
data from the clinical cohorts. We computed a second mania lesion 
network map using the clinical mania lesion cohort (n = 15) and the 
clinical control cohort of stroke lesions (n = 490), as described previ-
ously for the literature cohort. In the first step a simple conjunction 
analysis was performed, identifying connections significantly associ-
ated with mania in both the literature and clinical network maps. We 
then performed a single combined analysis in PALM comparing the 
literature and clinical mania lesion cohorts (n = 56) with the literature 
and clinical control cohorts (n = 569). Voxels significantly associated 
with mania across both cohorts were identified, including dimension 
(2D vs. 3D) as a covariate. Given extremely robust results, we applied a 
rigorous voxel-wise FWE correction at α less than 1 × 10–4 to highlight 
only the most significant findings. We identified peak coordinates in 
this map and ROIs greater than 200 mm3. Coordinates are reported in 
MNI atlas space and ROIs are labeled using the Harvard-Oxford atlas. 
Please see Supplemental Table 3 for further details.
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reports of DBS volume tissue activation (122), was centered at each the 
mentioned coordinates. Connectivity between each ROI and the com-
bined mania network map was computed (4, 117), and significant dif-
ferences in connectivity between mania-inducing and the respective 
DBS target were identified using a paired t test across the normative 
connectome (N = 1000) (4, 117).
Statistics. As detailed above, the following statistical tests were 
performed: voxel-wise permutation-based 2-sample t tests to com-
pare mania-derived and control-derived network maps; general lin-
ear models to test whether mania lesion map intersections differed 
across different cohorts, i.e., clinical mania, clinical controls, and 
other neuropsychiatric symptoms; Wilcoxon’s rank-sum and Wil-
coxon’s signed-rank tests to test reliability of lesion location and the 
therapeutic relevance of the mania lesion network, respectively; and 
paired t tests to test differences in connectivity between distinct TMS 
or DBS targets. Two-tailed P values are reported. Unless otherwise 
noted, hypothesis tests were interpreted considering a type I error 
probability of α less than 0.05.
Study approval. Data collection in the clinical cohort was approved by 
the ethics committee at Centro Hospitalar de Lisboa Ocidental, Lisbon, 
Portugal, in accordance with the Declaration of Helsinki, that, consid-
ering the retrospective nature of the study, waived the need for written 
informed consent. Data analysis was approved by the ethics committee 
at Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
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visual hallucinations (n = 42) (20). Importantly, none of these cohorts 
were used as controls in the primary analysis used to derive the mania 
connectivity map. To test whether intersection with the mania lesion 
map, i.e., sum of voxel intensities, differed across lesion cohorts, we 
performed a general linear model controlling for lesion size, bootstrap-
ping the standard error estimates (2000 permutations) (Stata Statis-
tical Software, release 15). In planned post hoc analyses, we tested 
whether lesion intersection with our map was significantly different 
from zero for each syndrome, as well as differences between specific 
pairs of syndromes.
Therapeutic relevance of the mania lesion network. To test whether 
the connectivity profile derived from lesion locations might relate 
to mania-related clinical responses to high-frequency rTMS (32–37), 
the connectivity between a priori ROIs representing the left and right 
DLPFC and the combined mania network map was computed (4, 117). 
The a priori ROIs were the left and right middle frontal gyri selected 
from the Harvard-Oxford Cortical Structural Atlas, selected to align 
with the locations of brain stimulation previously reported to induce 
(left DLPFC) or relieve (right DLPFC) mania symptoms (32–37). Since 
the atlas parcellations are defined according to the voxel probability of 
being included in the ROI, we used a 95% confidence interval threshold 
(114) to discard voxels that could be located outside of the brain or over-
lapping with other ROIs. The a priori ROIs thus defined are sufficiently 
large to account for variability in stimulation site across subjects, occur-
ring due to different methods for target localization and when brain 
stimulation treatments are performed without neuronavigation (118). 
We then tested significant differences between left and right DLPFC 
connectivity to the mania network map, using a paired t test across the 
connectome (N = 1000), as described elsewhere (4, 117).
To further explore the therapeutic relevance of the mania network 
map, we reviewed available literature focusing on rTMS trials for mania 
treatment, reporting the target localization method. We found 4 trials, 
all using right-sided targets, 3 of which with target localization using 
the 5-cm rule (34, 35, 38) and 1 using the EEG F4 coordinate (39). Since 
none used neuronavigation, we extracted the average MNI coordinates 
for both methods from previous reports: (MNI –41, 16, 54) for the 5-cm 
method (117) and (MNI 36, 44, 32) for the EEG F4 coordinate (119). 
After creating a 10-mm spherical ROI (120) centered at each coordinate, 
we computed the connectivity between these ROIs and the combined 
mania network map (4, 117), and tested significant differences between 
the 2 using a paired t test across the connectome (N = 1000) (4, 117).
In another exploratory approach we reviewed the literature to 
focus on cases of DBS-induced mania reporting target stimulation 
coordinates. Specifically, we tested if the combined mania network 
map differentiates DBS targets associated with mania from the aver-
age targets, as reported in the literature. We found 5 reports of mania 
after VC/VS stimulation in patients with obsessive-compulsive disor-
der (41–44) and 4 reports of mania after STN stimulation in Parkin-
son’s disease patients (47–49), that included stimulation coordinates. 
Coordinates were mapped into MNI space using Lead-DBS software 
(www.lead-dbs.org) (45, 121). We then averaged the mania-inducing 
coordinates in the VC/VS (MNI right 10.19, 3.05, –5.69 | left: –9.94, 
3.97, –4.13) and STN (MNI right: 11.44, –15.41, –8.57 | left: –11.75, 
–15.94, –8.8). Average standard/typical DBS target locations were also 
defined from previous reports of VC/VS (MNI right: 13, 8, –2 | left: –13, 
8, –1) (50) and STN (MNI right: 12.58, –13.41, –5.87 | left: –12.58, –13.41, 
–5.87) (45) DBS. A 3-mm spherical ROI, approximating previous 
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